Table 4.

Univariate analysis of survivals.

Variable		OS			RFS
		HR	95% CI	p-Value	HR	95% CI	p-Value
Age (years)
	<55	1			1
	≥55	2.07	1.31–3.27	0.001	1.43	0.89–2.31	0.137
Tumor size
	T1	1			1
	T2/T3/T4	2.82	1.75–4.55	<0.001	2.59	1.55–4.34	<0.001
Nodal status
	N−	1			1
	N+	2.25	1.48–3.42	<0.001	4.34	2.67–7.05	<0.001
Histological grade
	1–2	1			1
	3	0.79	0.50–1.26	0.328	1.02	0.59–1.76	0.931
Histology
	Ductal	1			1
	Other	0.61	0.33–1.15	0.108	0.91	0.49–1.69	0.764
Adjuvant chemotherapy
	No	1			1
	Yes	0.33	0.21–0.50	<0.001	0.5	0.31–0.81	0.007
Basal-like phenotype
	No	1			1
	Yes (basal)	1.06	0.68–1.66	0.787	0.85	0.53–1.36	0.495
Molecular apocrine phenotype
	No	1			1
	Yes (molecular apocrine)	1.6	1.04–2.46	0.033	1.65	1.03–2.63	0.038
TILs
	<5%	1			1
	≥5%	0.52	0.33–0.80	0.003	0.47	0.29–0.76	0.002
CD3+ density
	Low	1			1
	High	0.72	0.47–1.10	0.126	0.64	0.40–1.02	0.059
CD8+ density
	Low	1			1
	High	1.11	0.72–1.70	0.634	0.91	0.57–1.45	0.696
PD-L1TC
	<1%	1			1
	≥1%	0.66	0.42–1.02	0.061	0.59	0.37–0.96	0.034
PD-L1SC
	<10%	1			1
	≥10%	0.67	0.42–1.06	0.081	0.57	0.35–0.95	0.028
PD-1SC
	<10%	1			1
	≥10%	1.09	0.71–1.67	0.708	0.92	0.57–1.47	0.725
CD11b density
	Low	1			1
	High	0.72	0.46–1.12	0.141	0.66	0.40–1.07	0.088
CD66b density
	Low	1			1
	High	1.29	0.83–2.01	0.251	1.2	0.74–1.93	0.456
CXCR2 density
	Low	1			1
	High	0.61	0.40–0.95	0.026	0.52	0.32–0.85	0.007

Footnote: OS: overall survival; RFS: relapse-free survival; HR: hazard ratio; CI: confidence interval; Basal-like phenotype was considered in the case of positive staining for cytokeratin 5/6 and/or EGFR (>10% of tumor cells stained in IHC); Molecular apocrine phenotype was defined in TNBC tumors that express both androgen receptor (AR) and Forkhead box protein A1 (FOXA1) biomarkers; TILs: tumor-infiltrating lymphocytes; PD-L1: programmed cell death ligand 1; PD-1: programmed cell death 1; TC: tumor cells; SC: stromal cells.